Literature DB >> 15370608

Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.

Ingfrid Salvesen Haldorsen1, Jan Harald Aarseth, Aase Hollender, John Ludvig Larsen, Ansgar Espeland, Olav Mella.   

Abstract

The incidence of primary central nervous system lymphoma (PCNSL) has been reported to increase in some parts of the world, while being stable in other regions. In an attempt to characterize the incidence rate, clinical features, treatment, outcome, and prognostic factors of PCNSL in Norway, we report our experience in a large unselected series of patients. Clinical features, histological diagnosis, radiological findings, treatment, and outcome of all patients diagnosed with PCNSL in Norway in the years 1989-1998 were registered. During the 10-year period 58 new cases of histologically verified PCNSL were registered in Norway. The annual incidence rate of PCNSL was on average 1.34 cases per million people with a non-significant increasing trend (p=0.069). For patients diagnosed before death (n=45) the estimated survival following histological diagnosis was 55%, 47%, and 23% at 1, 2, and 5 years, respectively. In Cox-regression analysis age, WHO performance status and treatment had independent prognostic impact on survival. In the studied decade, there was a non-significant trend towards increased incidence of PCNSL, perhaps due to increased availability of diagnostic imaging, especially magnetic resonance imaging.

Entities:  

Mesh:

Year:  2004        PMID: 15370608     DOI: 10.1080/02841860410015640

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  1 in total

1.  Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience.

Authors:  Chaitanya Krishna Puligundla; Stalin Bala; Ashok Kumar Karnam; Sadashivudu Gundeti; Tara Roshni Paul; Megha S Uppin; Lakshmi Srinivas Maddali
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.